Although our previous data showed no defect in the proliferation capacity and pSTAT5 activation of different lymphocyte subsets from melanoma patients compared to healthy controls, there could be impairment in other IL-2-induced effector functions, such as inflammatory cytokine production. The gene discussed is IL2; the disease is melanoma.